EI
RNAM

EAM Investors’s Avidity Biosciences RNAM Stock Holding History

EAM Investors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-90,654
Closed -$4.16M – 338
2024
Q3 		$4.16M Buy
90,654
+19
+0% +$825 0.62% 64
2024
Q2 		$3.7M Buy
+90,635
New +$2.6M 0.6% 76

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's RNAM Position: Q4 2024 in Review

EAM Investors sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 90,654 shares — an estimated $4.16M sold.

EAM Investors first reported a position in RNAM in Q2 2024 and held it in 2 quarters. The position peaked at $4.16M in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • EAM Investors reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 90,654 Avidity Biosciences shares in Q4 2024, an estimated $4.16M.
  • EAM Investors first reported a position in Avidity Biosciences in Q2 2024 and held it in 2 quarters.
  • EAM Investors's Avidity Biosciences position peaked at $4.16M in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.